Neuronascent is developing a new class of neurogenic therapeutics that reverses the cognitive deficit in AD patients by stimulating and protecting new neuron growth. Current drugs for Alzheimer's patients only affect the symptoms of the disease and may temporarily slow the disease progression without reversing the decline. Neuronascent's chemically-diverse, orally-active neurogenic lead therapeutic aims to promote the formation of new neurons and replace damaged neurons in key degenerating regions of the brain. Laboratory tests indicate that the lead therapeutic candidate promotes new brain cells that will survive under many neurodegenerative conditions. Our AD program is in the preclinical phase of development, initiating IND-enabling studies.

"More than 5 million Americans are living with Alzheimer's disease, a 10 percent increase since the last Alzheimer's Association estimate five years ago on track for skyrocketing Alzheimer's once the baby boomers start turning 65 in 2011."
- ASSOCIATED PRESS, MARCH 20, 2007

The direct and indirect cost of AD to society is approximately $100 billion annually. Present AD therapies moderately slow the progression of the disease, without reversing the deficit or improving cognition.

For more information on Alzheimer's disease, please visit the Alzheimer's Association at www.alz.org.”